US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

17.17

-0.2900-1.66%

Post-market: 17.170.00000.00%19:30 EDT

Volume:436.83K

Turnover:7.57M

Market Cap:2.22B

PE:-7.62

High:17.96

Open:17.52

Low:17.00

Close:17.46

52wk High:28.23

52wk Low:16.39

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.45

T/O Rate:0.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.99

PE(LYR):0.00

Loading ...

Overview Company News Filings

Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535

Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial

THOMSON REUTERS

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535

THOMSON REUTERS

Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight

THOMSON REUTERS

Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027

THOMSON REUTERS

Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535

THOMSON REUTERS

Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks

THOMSON REUTERS

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)

TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M

Benzinga Earnings

Kailera Q1 FY26 net loss more than quadruples to $78.87 million

Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln

THOMSON REUTERS

Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials

THOMSON REUTERS

Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028

THOMSON REUTERS

Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen

Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/KLRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":17.17,"timestamp":1787342400000,"preClose":17.46,"halted":0,"volume":436830,"hourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.17,"latestTime":"19:30 EDT","volume":2129,"amount":36551.25,"timestamp":1787355007970,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016609392898052643,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Market Closed","change":-0.29,"latestTime":"08-21 16:00:00 EDT","open":17.52,"high":17.96,"low":17,"amount":7570552.207800001,"amplitude":0.054983,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":17.46,"preHourTrading":{"tag":"盘前","latestPrice":17.8,"preClose":17.46,"latestTime":"08:04 EDT","volume":12,"amount":213.55998,"timestamp":1787313854187,"change":0.34,"changeRate":0.019473,"amplitude":0.028637},"postHourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.17,"latestTime":"19:30 EDT","volume":2129,"amount":36551.25,"timestamp":1787355007970,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4456496744289272},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.4456496744289272,"shares":129537300,"dividePrice":0,"high":17.96,"amplitude":0.054983,"preClose":17.46,"low":17,"week52Low":16.39,"pbRate":"1.99","week52High":28.2271,"institutionHeld":0,"latestPrice":17.17,"eps":-2.254252,"divideRate":0,"volume":436830,"delay":0,"ttmEps":-2.254252,"open":17.52,"prevYearClose":16,"prevWeekClose":17.94,"prevMonthClose":16.94,"prevQuarterClose":22.03,"fiveDayClose":17.94,"twentyDayClose":17.69,"sixtyDayClose":21.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-08-21","current":-7.616717,"percent":1,"low":-21.871461,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"high":-7.746755,"avg":-15.438559,"sd":4.169763,"marketCap":2263578582},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582}],"updateTime":1787506987051},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649398103","title":"Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649398103","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649398103?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:02","pubTimestamp":1783422136,"startTime":"0","endTime":"0","summary":"Kailera reports Phase 3 China data showing up to 10.9% weight loss with oral GLP-1 drug KAI-7535Kailera reported positive topline Phase 3 results in China for oral GLP-1 agonist HRS-7535, also known a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL1K8vr9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["80016","BK4585","IE00B1G9TM23.USD","LU0061477393.USD","LU0096374516.USD","LU2088748020.USD","BK1521","BCDF","LU1504937902.USD","LU2088748376.SGD","LU2088747998.USD","BK1601","LU2095319765.USD","LU2226123490.SGD","BK4588","BK1559","00016","LU2088748293.HKD","SG9999002463.SGD","IE00B64PRP62.GBP","03121","LU0886674414.USD","BK1216","SG9999014005.SGD","IE00BSPPW651.USD","LU1316543674.SGD","LU1560770973.SGD","NDAQ","SG9999010052.SGD","SG9999014021.USD","LU2226123227.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SUHJY","LU1163227579.USD","LU0315179316.USD","OZEM","LU0229494975.USD","LU1163227496.USD","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","03145","BK4139","SG9999009997.SGD","KLRA","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981789","title":"Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981789?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981749","title":"Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981749?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649817599","title":"Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2649817599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649817599?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649598173","title":"Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2649598173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649598173?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649498176","title":"Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649498176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649498176?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537613","title":"Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537613?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641812390","title":"Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641812390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641812390?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:37","pubTimestamp":1780702671,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123920","title":"Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123920","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123920?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:32","pubTimestamp":1780702320,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307661/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Present-Ribupatide-Clinical-Data-at-ADA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4123","LU1169589451.USD","BK4218","LU1169590202.USD","AUC","BK4181","KLRA","PD","BK4139","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639168796","title":"Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639168796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639168796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303260/0/en/Kailera-Therapeutics-to-Present-at-the-2026-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","XLV","KLRA","BK4137","XBI","BK4588","LU0029874061.USD","BK4585","BK4581","BK4139","HCSG","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697868","title":"Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697868?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:55","pubTimestamp":1779983733,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Kailera Therapeutics, Inc. today and set a price target of $48.00. Song covers the Healthca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638673576","title":"TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638673576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638673576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:15","pubTimestamp":1779858913,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Kailera Therapeutics, Inc. yesterday. The company’s shares closed yesterday at USD21.57. W...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638052823","title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2638052823","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638052823?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:50","pubTimestamp":1779828607,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&amp;D spend Jumps to $70.9M.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52795466/kailera-therapeutics-q1-eps-3-65-misses-0-68-estimate-as-r-d-spend-jumps-to-70-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540348","title":"Kailera Q1 FY26 net loss more than quadruples to $78.87 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540348","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540348?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825771,"startTime":"0","endTime":"0","summary":"Kailera posted a net loss of $78.87 million in Q1 2026, widening from a $17.98 million loss a year earlier.Research and development expenses more than doubled to $70.87 million, while general and administrative costs rose 33.88% to $13.79 million.Cash, cash equivalents and marketable securities totaled $581.9 million as of March 31, with IPO proceeds expected to fund operations into mid-2028.Advanced obesity pipeline with five late-stage global trials initiated, including the KaiNETIC Phase 3 program for once-weekly ribupatide injection.Reported new partner-led topline data in China for oral GLP-1 agonist KAI-7535 in type 2 diabetes and first-in-human Phase 1 results for injectable tri-agonist KAI-4729.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLpWX5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2088747998.USD","SG9999014039.USD","BK1559","SG9999002463.SGD","BK4139","LU0229494975.USD","IE00BN0W2V16.EUR","BK1601","IE00BSPPW651.USD","LU1560770973.SGD","KLRA","LU1163227496.USD","LU0315179316.USD","BK1521","BK4588","IE00B1G9TM23.USD","LU0224508324.USD","IE00BN0W2W23.USD","LU2095319765.USD","LU2226123227.USD","03145","IE00BGHQF748.EUR","LU0314104364.USD","LU0886674414.USD","NDAQ","BK1216","IE00BN0W2T93.GBP","LU2088748293.HKD","SG9999009997.SGD","LU2088748020.USD","BK4112","BK4585","IE00B64PRP62.GBP","80016","LU1163227579.USD","LU1539696804.USD","LU2210150020.SGD","SG9999014005.SGD","LU0096374516.USD","SG9999014013.SGD","LU2226123490.SGD","SG9999010078.USD","LU2088747725.USD","LU2088748376.SGD","SUHJY","00016","SG9999010052.SGD","IE00B1G9TL16.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540558","title":"Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540558?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540510","title":"Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540510?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638154062","title":"Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2638154062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638154062?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540384","title":"Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540384","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540384?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":"-- Important progress across four clinical-stage programs demonstrating. -- Initiated five late-stage global clinical trials in obesity, including. -- Reported positive topline clinical data from three trials conducted by. our partner Hengrui in China, including new topline data from Phase 3. trial of oral small molecule GLP-1 receptor agonist HRS-7535 . in type 2 diabetes, and first-in-human topline data from Phase 1 trial. -- Cash on hand, including IPO proceeds, is expected to fund operations into. Renaud, continued, \"These achievements, combined with our successful IPO, have positioned us with the capital and operational strength to continue advancing multiple programs in parallel. We are focused on maintaining this momentum and executing across our clinical programs as we work to deliver differentiated therapies for the treatment of obesity.\". living with obesity or overweight. Data is anticipated in 2028.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","BMI","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637353143","title":"Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353143?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:55","pubTimestamp":1779382537,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $57.00. Werber...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","BK4127","KLRA","BK4566","BK4585","COWN","BK4139","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636418018","title":"Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636418018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636418018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:41","pubTimestamp":1779036113,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4141","NA","BK4187","ARXS","KLRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}]}}